cabazitaxel "medac" 20 mg/ml koncentrat til infusionsvæske, opløsning
medac gesellschaft für klinische spezialpräparate mbh - cabazitaxel - koncentrat til infusionsvæske, opløsning - 20 mg/ml
cabazitaxel "viatris" 20 mg/ml koncentrat til infusionsvæske, opløsning
viatris limited - cabazitaxel - koncentrat til infusionsvæske, opløsning - 20 mg/ml
cabazitaxel teva
teva b.v. - cabazitaxel - prostatiske neoplasmer - antineoplastiske midler - behandling af prostatakræft.
jevtana
sanofi winthrop industrie - cabazitaxel - prostatiske neoplasmer - antineoplastiske midler - jevtana i kombination med prednison eller prednisolon er indiceret til behandling af patienter med hormon-ildfast metastatisk prostatacancer, der tidligere er behandlet med en docetaxelholdig behandling.
xtandi
astellas pharma europe b.v. - enzalutamide - prostatiske neoplasmer - endokrine terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
ketoconazole hra
hra pharma rare diseases - ketoconazol - cushing syndrome - antimykotika til systemisk brug - ketoconazol hra er indiceret til behandling af endogent cushings syndrom hos voksne og unge over 12 år.
tafinlar
novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuverende behandling af melanomadabrafenib i kombination med trametinib er angivet for den adjuverende behandling af voksne patienter med stadium iii melanom med en braf v600 mutation, efter komplet resektion. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
niddazol 100 mg kapsler, hårde
stada arzneimittel ag - itraconazol - kapsler, hårde - 100 mg
sporanox 100 mg kapsler
janssen-cilag a/s - itraconazol - kapsler - 100 mg
cabazitaxel "medical valley" 40 mg/ml koncentrat og solvens til infusionsvæske, opløsning
medical valley invest ab - cabazitaxel - koncentrat og solvens til infusionsvæske, opløsning - 40 mg/ml